OBIO Orchestra BioMed Holdings Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: OBIO

Price (delayed)

$4.39

Market cap

$157.06M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.48

Enterprise value

$128.19M

Highlights
Orchestra BioMed Holdings's debt has plunged by 86% YoY and by 85% from the previous quarter
Orchestra BioMed Holdings's quick ratio has surged by 73% YoY and by 54% QoQ
The equity has grown by 30% YoY but it has contracted by 15% from the previous quarter
OBIO's net income is down by 46% YoY and by 7% QoQ
The company's gross profit fell by 24% QoQ and by 23% YoY
Sector: Healthcare
Industry: Medical Devices
Peers: OM

Key stats

What are the main financial stats of OBIO
Market
Shares outstanding
35.78M
Market cap
$157.06M
Enterprise value
$128.19M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.31
Price to sales (P/S)
52.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
46.45
Earnings
Revenue
$2.76M
EBIT
-$49.12M
EBITDA
-$48.2M
Free cash flow
-$46.21M
Per share
EPS
-$1.48
Free cash flow per share
-$1.39
Book value per share
$1.9
Revenue per share
$0.08
TBVPS
$2.87
Balance sheet
Total assets
$95.21M
Total liabilities
$27.17M
Debt
$1.69M
Equity
$68.04M
Working capital
$77.91M
Liquidity
Debt to equity
0.02
Current ratio
7.95
Quick ratio
7.82
Net debt/EBITDA
0.6
Margins
EBITDA margin
-1,746.4%
Gross margin
93.3%
Net margin
-1,779.7%
Operating margin
-1,866.2%
Efficiency
Return on assets
-41.5%
Return on equity
-58.3%
Return on invested capital
-53.3%
Return on capital employed
-58.5%
Return on sales
-1,779.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

OBIO stock price

How has the Orchestra BioMed Holdings stock price performed over time
Intraday
-1.13%
1 week
-5.39%
1 month
-16.54%
1 year
-70.91%
YTD
-51.92%
QTD
-16.7%

Financial performance

How have Orchestra BioMed Holdings's revenue and profit performed over time
Revenue
$2.76M
Gross profit
$2.57M
Operating income
-$51.51M
Net income
-$49.12M
Gross margin
93.3%
Net margin
-1,779.7%
OBIO's operating margin has shrunk by 102% YoY and by 38% QoQ
Orchestra BioMed Holdings's net margin has plunged by 87% YoY and by 39% from the previous quarter
The operating income has dropped by 58% year-on-year and by 5% since the previous quarter
OBIO's net income is down by 46% YoY and by 7% QoQ

Growth

What is Orchestra BioMed Holdings's growth rate over time

Valuation

What is Orchestra BioMed Holdings stock price valuation
P/E
N/A
P/B
2.31
P/S
52.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
46.45
Orchestra BioMed Holdings's EPS has increased by 34% YoY and by 6% from the previous quarter
The price to book (P/B) is 48% lower than the last 4 quarters average of 4.4
The equity has grown by 30% YoY but it has contracted by 15% from the previous quarter
OBIO's price to sales (P/S) is 46% less than its last 4 quarters average of 98.1
Orchestra BioMed Holdings's revenue has decreased by 23% QoQ and by 22% YoY

Efficiency

How efficient is Orchestra BioMed Holdings business performance
Orchestra BioMed Holdings's ROS has plunged by 87% YoY and by 30% from the previous quarter
The company's return on assets has shrunk by 63% YoY and by 7% QoQ
Orchestra BioMed Holdings's return on invested capital has shrunk by 55% YoY and by 3.7% QoQ

Dividends

What is OBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OBIO.

Financial health

How did Orchestra BioMed Holdings financials performed over time
OBIO's current ratio has surged by 74% year-on-year and by 55% since the previous quarter
Orchestra BioMed Holdings's quick ratio has surged by 73% YoY and by 54% QoQ
Orchestra BioMed Holdings's debt is 98% less than its equity
The debt to equity has shrunk by 91% YoY and by 86% QoQ
Orchestra BioMed Holdings's debt has plunged by 86% YoY and by 85% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.